Veristat opens office in Taiwan to support ‘fast-growing' clinical development market
According to the Massachusetts-based clinical development, and regulatory submission company, the new location – chosen after a year of evaluating sites – matches the companies values and culture for partnership and innovation.
“Veristat decided to expand into the Asian market to support regional and international client demand for statistical expertise as companies prepare their clinical trial data for submission to global health authorities,” Patrick Flanagan, Veristat CEO, told us.
Veristat is creating a team of statistical programmers and clinical trial professionals at the office as demand for local and international regulatory submission support increases.
According to Flanagan, the company hired its first employees to the Taipei office in 2018. “The recent office opening provides a stable base for our current team to grow and expand the services offered in Taipei,” he said.
The company currently has biostatisticians and statistical programming professionals in the Taipei office, and will add clinical professionals as the company grows its local clientele.
As Veristat’s operations continue to grow in the region, Philip Ho will serve as director of Taipei operations and manager of statistical programming for the company. Ho’s experience in the industry includes database and statistical programming in Asia. He was a member of statistical programming teams for contract research organizations (CROs) in China, which has been growing into a hub for the drug development and clinical trials industry.
Ho said, “Establishing a footprint in Taipei allows local Veristat programmers to support the fast-growing clinical development market in Taiwan. My team is growing to support submission programs for both local sponsors, as well as our North American sponsors.”
Ashish Jain VP and head of Asia Pacific at Premier Research previously told us that economic growth in the Asia-Pacific region has enabled greater health care spending and greater patient access to new drugs amplifying demand in the area.
Taiwan also has a large and treatment-naïve patient population because of the previous regulatory environment in the region, according to Jain.
